Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer-Reference-Cited by-同舟云学术

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer

Published:2017-01-01 Issue:1 Volume:22 Page:70-80
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

O’Kane Grainne M.¹,Labbé Catherine¹,Doherty Mark K.¹,Young Kelvin¹,Albaba Hamzeh¹,Leighl Natasha B.¹

Affiliation:

1. Department of Medical Oncology and Hematology Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada

Abstract

Abstract Monoclonal antibodies targeting programmed cell death protein-1 (PD-1) represent a new treatment paradigm in non-small cell lung cancer. Three phase III trials have demonstrated a survival benefit and improved tolerability of nivolumab and pembrolizumab when compared with standard second-line chemotherapy. Nevertheless, the adverse events associated with PD-1 inhibitors are unique; early recognition and treatment are essential. This review summarizes the required monitoring and appropriate management of immune-related adverse events in lung cancer patients receiving these agents.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2016-0164

Reference68 articles.

1. Management of immune checkpoint blockade dysimmunetoxicities: A collaborative position paper;Champiat;Ann Oncol,2016

2. Managing treatment-related adverse events associated with Alk inhibitors;Rothenstein;Curr Oncol,2014

3. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

4. PD-L1 over-expression and survival in patients with non-small cell lung cancer: A meta-analysis;Zhou;Transl Lung Cancer Res,2015

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Immunotherapy in Non-Small-Cell Lung Cancer;Current Oncology;2024-06-17

2. Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis;Cancers;2024-03-13

3. 建立和验证非小细胞肺癌PD-1/PD-L1抑制剂相关不良反应的风险预测模型;Journal of Zhejiang University-SCIENCE B;2023-10

4. A 67-Year-Old Man with Grade 3 Reactive Cutaneous Capillary Endothelial Proliferation Induced by Camrelizumab First Manifested in the Oral Mucosa – A Case Report;International Journal of Surgical Pathology;2023-09-18

5. Radiological assessment of immunotherapy effects and immune checkpoint‐related pneumonitis for lung cancer;Journal of Cellular and Molecular Medicine;2023-07-31